Evidence map›Paper›PMID 27737742›Full record

ArticleJournal of the American College of Cardiology2016

Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.

Tal Lorberbaum, Kevin J Sampson, Jeremy B Chang, Vivek Iyer, Raymond L Woosley, Robert S Kass, Nicholas P Tatonetti

Abstract read
In one paragraph

Article in Journal of the American College of Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 79 citations in OpenAlex.

  1. Observational
  2. A Cautionary Tale of Combination Ceftriaxone and Lansoprazole: Should Pediatric Clinicians Heed the Warning?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  3. Pro-arrhythmic potential of proton-pump inhibitors.Nature reviews. Cardiology · 2025
    Article
  4. Applications of Artificial Intelligence in Drug Repurposing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions.Journal of the American Medical Informatics Association : JAMIA · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tal LorberbaumDepartment of Physiology and Cellular Biophysics, Columbia University, New York, New York; Department of Biomedical Informatics, Columbia University, New York, New York.
Kevin J SampsonDepartment of Pharmacology, Columbia University, New York, New York.
Jeremy B ChangDepartment of Biomedical Informatics, Columbia University, New York, New York.
Vivek IyerDepartment of Cardiology, Columbia University, New York, New York.
Raymond L WoosleyAzcert, Inc., Oro Valley, Arizona.
Robert S KassDepartment of Pharmacology, Columbia University, New York, New York.
Nicholas P TatonettiDepartment of Biomedical Informatics, Columbia University, New York, New York. Electronic address: nick.tatonetti@columbia.edu.
Columbia University · US

Funding

Training in Biomedical Informatics at Columbia UniversityT15LM007079 · NLM · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI NOEMIE ELHADAD, GEORGE M HRIPCSAK · 1992 to 2026
$28.9M
Systematic pharmacological targeting of the core mechanisms responsible for maintaining cancer cell stateU54CA209997 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA, HONIG, BARRY H · 2016 to 2021
$10.9M
Modulation of KCNQ1 channel activityR01GM109762 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI KASS, ROBERT S, LARSSON, HANS PETER · 2014 to 2022
$3.1M
Drug Effect Discovery Through Data Mining and Integrative Chemical BiologyR01GM107145 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TATONETTI, NICHOLAS P · 2014 to 2018
$2.5M
Training Program in Computational BiologyT32GM082797 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HONIG, BARRY H · 2008 to 2015
$1.4M
Cell-type Specificity of Heritable Channelopathies: Role of the Purkinje FiberK08HL116790 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IYER, VIVEK · 2013 to 2017
$728k
NCI NIH HHS U54 CA209997NHLBI NIH HHS K08 HL116790NIGMS NIH HHS R01 GM107145NIGMS NIH HHS R01 GM109762NIGMS NIH HHS T32 GM082797NLM NIH HHS T15 LM007079
6 · The paper itself

Abstract

backgroundQT interval-prolonging drug-drug interactions (QT-DDIs) may increase the risk of life-threatening arrhythmia. Despite guidelines for testing from regulatory agencies, these interactions are usually discovered after drugs are marketed and may go undiscovered for years.

objectivesUsing a combination of adverse event reports, electronic health records (EHR), and laboratory experiments, the goal of this study was to develop a data-driven pipeline for discovering QT-DDIs.

methods1.8 million adverse event reports were mined for signals indicating a QT-DDI. Using 1.6 million electrocardiogram results from 380,000 patients in our institutional EHR, these putative interactions were either refuted or corroborated. In the laboratory, we used patch-clamp electrophysiology to measure the human ether-à-go-go-related gene (hERG) channel block (the primary mechanism by which drugs prolong the QT interval) to evaluate our top candidate.

resultsBoth direct and indirect signals in the adverse event reports provided evidence that the combination of ceftriaxone (a cephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the QT interval. In the EHR, we found that patients taking both ceftriaxone and lansoprazole had significantly longer QTc intervals (up to 12 ms in white men) and were 1.4 times more likely to have a QTc interval above 500 ms. In the laboratory, we found that, in combination and at clinically relevant concentrations, these drugs blocked the hERG channel. As a negative control, we evaluated the combination of lansoprazole and cefuroxime (another cephalosporin), which lacked evidence of an interaction in the adverse event reports. We found no significant effect of this pair in either the EHR or in the electrophysiology experiments. Class effect analyses suggested this interaction was specific to lansoprazole combined with ceftriaxone but not with other cephalosporins.

conclusionsCoupling data mining and laboratory experiments is an efficient method for identifying QT-DDIs. Combination therapy of ceftriaxone and lansoprazole is associated with increased risk of acquired long QT syndrome.

Indexed as

Data MiningAgedCeftriaxoneCefuroximeDrug InteractionsDrug-Related Side Effects and Adverse ReactionsElectronic Health RecordsElectrophysiologic Techniques, CardiacFemaleHumansLansoprazoleLong QT SyndromeMaleMiddle AgedPatch-Clamp TechniquesProton Pump InhibitorsCeftriaxoneCefuroximeLansoprazoleProton Pump Inhibitorsdata miningdata sciencedrug-drug interactionlong QT syndrome

Identifiers

PMID27737742
PMCPMC5082283
OpenAlexW2530398232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.